Research programme: human papillomavirus infections - VIRxSYS/NCI
Latest Information Update: 28 Sep 2007
At a glance
- Originator Intronn; National Cancer Institute (USA)
- Developer National Cancer Institute (USA); VIRxSYS Corporation
- Class
- Mechanism of Action RNA stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cervical cancer; Human papillomavirus infections
Most Recent Events
- 21 Sep 2007 Discontinued - Preclinical for Cervical cancer in USA (unspecified route)
- 21 Sep 2007 Discontinued - Preclinical for Human papillomavirus infections in USA (unspecified route)
- 21 Sep 2007 Intronn has been acquired and merged into VIRxSYS Corporation